

# Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

2025-04-28

LOS ANGELES--(BUSINESS WIRE)-- **Niagen Bioscience, Inc.** (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Wednesday, May 7, 2025, at 4:30 p.m. ET to discuss its financial results for the first quarter 2025, which ended March 31, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours on Wednesday, May 7, 2025.

## Investor Conference Call:

Niagen Bioscience management will host an investor conference call to discuss the first quarter 2025 financial results and provide a general business update on Wednesday, May 7, 2025, at 4:30 p.m. ET. Participants should call in at least 10 minutes before the call. The dial-in information is as follows:

Date: Wednesday, May 7, 2025

Time: 4:30 p.m. ET (1:30 p.m. PT)

Toll-free dial-in number: +1 888 596 4144

Conference ID: 8584242

Webcast link: **Niagen Bioscience First Quarter 2025 Earnings Conference Call**

The conference call will be broadcast live and available for replay **here** and via the investor relations section of the

Company's website at [www.niagenbioscience.com](http://www.niagenbioscience.com).

A replay of the conference call will be available from 7:30 p.m. ET on Wednesday, May 7, 2025, to 11:59 p.m. ET on Wednesday, May 14, 2025. The replay dial-in information is as follows:

Toll-free replay number: +1 800 770 2030

Replay ID: 8584242

For additional information on Niagen Bioscience, visit [www.niagenbioscience.com](http://www.niagenbioscience.com).

## About Niagen Bioscience:

**Niagen Bioscience, Inc.** (NASDAQ: NAGE), formerly ChromaDex Corp., is the global leader in NAD<sup>+</sup> (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD<sup>+</sup> discoveries, Niagen Bioscience™ is dedicated to advancing healthspan through precision science and innovative NAD<sup>+</sup>-boosting solutions.

The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD<sup>+</sup>. A vital coenzyme found in every cell of the human body, NAD<sup>+</sup> declines with age and exposure to everyday lifestyle stressors. NAD<sup>+</sup> depletion is a key contributor to age-related changes in health and vitality.

Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There's a better way to age.

At the heart of its clinically proven product portfolio is Niagen® (patented nicotinamide riboside, or NR), the most efficient, well-researched, high-quality, and legal NAD<sup>+</sup> booster available. Niagen powers the Company's consumer supplement, Tru Niagen®, the number one NAD<sup>+</sup> boosting oral supplement in the United States<sup>†</sup> (available at [www.truniagen.com](http://www.truniagen.com)), and Niagen Plus™, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products ([www.niagenplus.com](http://www.niagenplus.com)). Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription.

Niagen Bioscience's robust patent portfolio protects NR and other NAD<sup>+</sup> precursors. Niagen Bioscience maintains a website at [www.niagenbioscience.com](http://www.niagenbioscience.com), where copies of press releases, news, and financial information are regularly published.

† Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 1/1/2024 - 12/31/2024).

### Niagen Bioscience Media Contact:

Kendall Knysch, Senior Director of Media Relations & Partnerships

310.405.5227

**[kendall.knysch@niagenbio.com](mailto:kendall.knysch@niagenbio.com)**

### Niagen Bioscience Investor Relations Contact:

Ben Shamsian

Lytham Partners

646-829-9701

**[shamsian@lythampartners.com](mailto:shamsian@lythampartners.com)**

Source: Niagen Bioscience, Inc